There is reproducible structure here. There is no demonstrated explanation of dependency transfer, and no demonstrated policy improvement.

1. **Verdict per thread**

| Thread | Verdict | Justification | Strongest counterargument to my verdict |
|---|---|---|---|
| Lock-S finding | **WEAK** | A small inverse association on a selected panel; the patient-level interval and the claimed bound remain unvalidated. | It was externally tested under a frozen protocol, and all archived sensitivity estimates remain negative. That deserves more weight than an exploratory correlation. |
| Broad displacement phenomenon | **PROMISING** | Split-half ρ=0.887 and lineage-matched agreement 0.923 establish a repeatable pattern worth explaining. | Repeatability does not identify an environmental cause. Cohort and processing differences remain; sharing the same 2D reference can inflate split-half agreement. The underlying organoid–2D phenomenon is already published. |
| Lability as a gene property | **WEAK** | Medium-axis absolute differences reproduce strongly, but format-L reliability is modest and neither axis predicts the tested organoid shift usefully. | Medium split-half ρ=0.830 and format–medium ρ=0.360 suggest some stable gene-level structure. Six format models may estimate it poorly. |
| Policy loop | **DEAD** under the present project design | The executed pilot achieved q=0.00037 against 0.020—about **55-fold below threshold**—and its protocol compliance was rejected. No efficiency advantage exists. | A tiny, partly degenerate candidate family on seven models cannot refute adaptive research policies generally. It does refute treating this pilot as evidence for one. |

The [external result](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/lock_s/results/external_v1.json), [Broad results](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/generations/direct_v2.json), and [policy result](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/generations/pgen010/cycle_result.json) support those distinctions.

2. **The Broad null is adverse evidence, but not a direct refutation of Lock-S.**

The biggest problem is that these analyses estimate different quantities:

- **Lock-S:** patient-averaged **absolute rank displacement** within 207 genes, adjusted for absolute baseline strength.
- **Broad v2:** **signed difference of cohort means** in Chronos units across 249 genes.

Opposing shifts can cancel in the Broad endpoint while producing substantial absolute displacement. The Broad script also weights seven format contrasts directly, giving one of the six models double weight. Its baseline adjustment and residual-correlation calculation differ from the frozen estimator. These differences are explicit in the [Broad code](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/src/direct_analysis_v2.py:83) and [Lock-S protocol](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/lock_s/scientific_protocol_v1.json:10).

**What remains compatible:** for the Broad *unadjusted signed-shift endpoint*, the reported patient bootstrap gives **ρ ∈ [−0.060, +0.018]**, conditional on the observed L, fixed 2D reference, and selected genes. That interval does not cover uncertainty about a population-wide gene property. The adjusted estimate, −0.072, has no reported interval.

**Attenuation alone is an inadequate rescue.** Taking full-L reliability ≈0.48 literally gives attenuation √0.48≈0.69. A rough classical correction changes −0.023 to **−0.033**, with the conditional interval becoming approximately **[−0.086,+0.025]**. A latent association of magnitude 0.20 would ordinarily appear around 0.14, substantially larger than observed. These are approximations, especially for ranks and absolute differences.

My interpretation: **endpoint mismatch plus possible assay/cohort differences; meaningful negative evidence against a broad, portable L→transfer relationship.** The result is informative. It does not establish which explanation caused the discrepancy.

3. **The single decisive next analysis: replicate the actual Lock-S estimand in Broad.**

One harmonized analysis, followed by one patient-held-out confirmation:

- **Predictor:** reconstruct the frozen L from public minipool processed scores: average within each model first, then weight the **six models equally**.
- **Panel/reference:** retain the **same 207 genes**, frozen `AdherentMean` ordering, and absolute baseline-strength covariate. All 207 genes occur in the Downloads gene-effect header.
- **Endpoint:** rank each organoid’s dependencies within those 207 genes; calculate absolute normalized displacement from the frozen reference; average models within patient, then patients equally.
- **Estimator:** the frozen partial Spearman—Pearson correlation of OLS rank residuals, without reranking residuals.
- **Sample:** debug and assess attainable precision using **82 development models / 80 patients**. Freeze the analysis before accessing the reserved **28 organoid models / 26 patients**. Those counts come from metadata only. There are **26 reserved organoid patients, not 981**.
- **Inference:** 5,000 patient-cluster bootstrap draws; separately report sensitivity to the six predictor models. Keep secondary endpoints from replacing the primary.

**Kill criterion:** if the held-out 95% interval lies entirely inside **(−0.20,+0.20)**, terminate the claim that this measured L materially tracks the specified displacement endpoint. An interval wholly above +0.20 or below −0.20 supports a material directional association. Anything else is inconclusive; stop endpoint shopping.

This resolves the present comparison’s central ambiguity. It cannot establish causality or a universal gene property. The small held-out cohort may prevent a decisive result.

4. **Probability of meeting the full GOAL.md criteria: approximately 1%.**

That is a judgment, not a calibrated posterior. The obstacle is the conjunction: a qualifying explanatory result, valid external inference, an admissible policy task, two genuine improvement cycles, and a demonstrated practical efficiency margin including overhead. The present evidence has established none of the required policy advantage, and the biological connection is weak.

The [terminal determination](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/reviews/terminal_determination_xhigh_v3.md) correctly leaves scientific qualification unresolved and the joint goal incomplete. High audit scores measure conformity to review criteria; they do not measure biological promise.

**Expected ceiling:** a reproducible selected-panel atlas and a narrowly qualified negative or inverse-association result, potentially accompanied by a measurement-reliability analysis. The current package cannot securely claim even the patient-level external bound. A successful harmonized replication could support a bounded association claim; it would still leave the explanatory mechanism and policy-efficiency claims unsupported.

5. **Stop immediately**

- **Further policy generations on the seven-model atlas.** There is insufficient independent task diversity and no demonstrated advantage to refine.
- **Repeated review, scoring, and specification repair as the main activity.** More reviews cannot supply independent measurements.
- **Calling signed mean differences a replication of absolute rank displacement.**
- **Treating reproducible absolute differences as biological lability without separating assay noise, gene-specific variance, baseline strength, and library effects.** The medium result is especially vulnerable because it pools heterogeneous medium contrasts.
- **Searching this release further for within-model genome-wide format pairs or A→B→A histories.** The census has already answered that question.
- **Mechanistic storytelling or further manuscript polishing around −0.146.** Correct inference and one harmonized replication must determine what survives.

**OVERALL: NOT_PROMISING**  
**HONEST_SCORE: 18/100**